Literature DB >> 8157044

Pharmacokinetics of chlorpromazine and key metabolites.

P K Yeung1, J W Hubbard, E D Korchinski, K K Midha.   

Abstract

A study was carried out in 11 healthy young men to investigate the pharmacokinetics of chlorpromazine (CPZ) after a bolus intravenous (i.v.) dose (10 mg) and three single oral doses (25, 50 and 100 mg), with a washout period of two weeks between doses. Plasma levels of CPZ, CPZ N-oxide (CPZNO), CPZ sulfoxide (CPZSO) and both free and conjugated 7-hydroxy-CPZ (7-HOCPZ) were measured by extraction radioimmunoassays. CPZ exhibited multicompartmental pharmacokinetics in most subjects. There was wide between-subject variability in half life (11.05 h), volume of distribution (1215 l), volume of distribution at steady state (642 l) and mean residence time (8.88 h), whereas systemic clearance was somewhat less variable (76.6 l.h-1). All metabolites were present in measurable concentrations in the plasma of 9 of 11 subjects after i.v. CPZ, whereas free 7-HOCPZ was not detected in the other 2 individuals. With the exception of CPZNO, the biological half lives of the primary metabolites were longer than the half life of CPZ. After oral administration, the percentage of CPZ reaching the systemic circulation intact (F%) was very low (4-38%) and dose dependent. Moreover, both within-subject and between-subject variances were very high. The maximum plasma concentration (Cmax) and area under the plasma concentration versus time curve extrapolated to infinite time (AUC) showed evidence of nonlinearity, whereas half life did not appear to be dose dependent. These data suggest that the high degree of variability in the pharmacokinetics of CPZ is a result of extensive first pass metabolism rather than variation in half life.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8157044     DOI: 10.1007/bf00315316

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects.

Authors:  E Spina; M Ancione; A E Di Rosa; M Meduri; A P Caputi
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.

Authors:  R Fonne-Pfister; U A Meyer
Journal:  Biochem Pharmacol       Date:  1988-10-15       Impact factor: 5.858

Review 3.  Plasma level monitoring of antipsychotic drugs.

Authors:  T B Cooper
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

4.  Thin-layer chromatography of chlorpromazine metabolites. Attempt to identify each of the metabolites appearing in blood, urine and feces of chronically medicated schizophrenics.

Authors:  P Turano; W J Turner; A A Manian
Journal:  J Chromatogr       Date:  1973-01-17

5.  Effect of chlorpromazine and some of its metabolites on synthesis and turnover of catecholamines formed from 14 C-tyrosine in mouse brain.

Authors:  H Nybäck; G Sedvall
Journal:  Psychopharmacologia       Date:  1972

6.  Pharmacokinetics of chlorpromazine in normal volunteers.

Authors:  J C Loo; K K Midha; I J McGilveray
Journal:  Commun Psychopharmacol       Date:  1980

7.  Therapeutic monitoring of chlorpromazine. IV: Comparison of a new high-performance liquid chromatographic method with radioimmunoassays for parent drug and some of its major metabolites.

Authors:  K K Midha; J W Hubbard; J K Cooper; T Gurnsey; E M Hawes; G McKay; B S Chakraborty; P K Yeung
Journal:  Ther Drug Monit       Date:  1987-09       Impact factor: 3.681

8.  A comparison of two radioimmunoassays for 7-hydroxychlorpromazine: rabbit polyclonal antibodies vs. mouse monoclonal antibodies.

Authors:  P K Yeung; G McKay; I A Ramshaw; J W Hubbard; K K Midha
Journal:  J Pharmacol Exp Ther       Date:  1985-06       Impact factor: 4.030

9.  The metabolism of chlorpromazine N-oxide in man and dog.

Authors:  T J Jaworski; E M Hawes; G McKay; K K Midha
Journal:  Xenobiotica       Date:  1990-01       Impact factor: 1.908

10.  Radioimmunoassay for the N-oxide metabolite of chlorpromazine in human plasma and its application to a pharmacokinetic study in healthy humans.

Authors:  P K Yeung; J W Hubbard; E D Korchinski; K K Midha
Journal:  J Pharm Sci       Date:  1987-10       Impact factor: 3.534

View more
  16 in total

1.  Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein.

Authors:  Jun-Sheng Wang; Hao-Jie Zhu; John S Markowitz; Jennifer L Donovan; C Lindsay DeVane
Journal:  Psychopharmacology (Berl)       Date:  2006-06-30       Impact factor: 4.530

2.  Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 induction potential of drugs in vivo in humans.

Authors:  Kajsa P Persson; Susanne Ekehed; Charlotta Otter; E S Mareike Lutz; Jane McPheat; Collen M Masimirembwa; Tommy B Andersson
Journal:  Pharm Res       Date:  2006-11-22       Impact factor: 4.200

3.  Chlorpromazine-induced hepatotoxicity during inflammation is mediated by TIRAP-dependent signaling pathway in mice.

Authors:  Adarsh Gandhi; Tao Guo; Pranav Shah; Bhagavatula Moorthy; Romi Ghose
Journal:  Toxicol Appl Pharmacol       Date:  2012-12-11       Impact factor: 4.219

4.  The Impact of the Antipsychotic Medication Chlorpromazine on Cytotoxicity through Ca2+ Signaling Pathway in Glial Cell Models.

Authors:  Che-Sheng Chu; Yung-Shang Lin; Wei-Zhe Liang
Journal:  Neurotox Res       Date:  2022-04-19       Impact factor: 3.911

5.  Constitutively active 5-HT2/α1 receptors facilitate muscle spasms after human spinal cord injury.

Authors:  Jessica M D'Amico; Katherine C Murray; Yaqing Li; K Ming Chan; Mark G Finlay; David J Bennett; Monica A Gorassini
Journal:  J Neurophysiol       Date:  2012-12-05       Impact factor: 2.714

6.  Antipsychotic drugs inhibit the function of breast cancer resistance protein.

Authors:  Jun-Sheng Wang; Hao-Jie Zhu; John S Markowitz; Jennifer L Donovan; Hong-Jie Yuan; C Lindsay Devane
Journal:  Basic Clin Pharmacol Toxicol       Date:  2008-10       Impact factor: 4.080

7.  A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein-bound drugs and the impact of errors in plasma protein binding.

Authors:  Min Ye; Swati Nagar; Ken Korzekwa
Journal:  Biopharm Drug Dispos       Date:  2016-04       Impact factor: 1.627

Review 8.  Repurposing functional inhibitors of acid sphingomyelinase (fiasmas): an opportunity against SARS-CoV-2 infection?

Authors:  Pascal Le Corre; Gwenolé Loas
Journal:  J Clin Pharm Ther       Date:  2021-03-01       Impact factor: 2.145

9.  Repurposed antipsychotic chlorpromazine inhibits colorectal cancer and pulmonary metastasis by inducing G2/M cell cycle arrest, apoptosis, and autophagy.

Authors:  Fuyan Xu; Huizhi Xi; Mengya Liao; Yiqian Zhang; Hongbo Ma; Mengling Wu; Qiang Xue; Hongbao Sun; Yiwen Zhang; Yong Xia
Journal:  Cancer Chemother Pharmacol       Date:  2022-01-24       Impact factor: 3.333

10.  On the functionalization of benzo[e][2,1]thiazine.

Authors:  Kirill Popov; Tatyana Volovnenko; Julian Volovenko
Journal:  Beilstein J Org Chem       Date:  2009-09-02       Impact factor: 2.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.